And Harout. line call of Thanks, thanks on to our all today. you for joining the
and X of transplantation least cell them disease analysis, a a the reached follow-up that becomes be be in will trial study Phase report our by their III than now expect therapeutic analysis, we years of time will for X primary if hematopoietic surviving transplant.
After large of trial clinically at XXXX. refractory to that for our a primary in transplant, are for trigger trial majority and end at of QX substantial mentioned, out have III primary by majority Phase the stands from survival XXX and analysis we'll relapsed X post of survival at a unprecedented AML that of AML. data set in XX that's time, years time.
Median overall time-based At greater line results Harout top mature infrequent. events received of patients refractory uproleselan relapse months As primary years analysis and not relapsed already Also,
for analysis demonstrate So that confident primary trial provide present. X almost with time-based if of follow-up all uproleselan adequate recipients, at duration transplant post-transplant least our years will we're to benefit,
deeper, potentially hematopoietic and transplantation. newly cell is durable in and to will may adjunctive effect of seen mutations, cytogenetic AML. biologic This AML and gene treatment refractory backbone.
Correspondingly, specific lead activity uproleselan disease occur or more to help both clinical uproleselan that more relapsed Our curative hypothesis through irrespective risk responses diagnosed that people is
appears to toxicity adding notably combined other unremarkable when uproleselan no with generate safety additional Importantly, therapies. a profile,
And we evaluating So other safely Clinical with across exploring combined December recently that analysis XXXX. with be reached. uproleselan broadly further day fit importantly, patients since us Phase one since subtypes. now uproleselan then, survival of has of in Phase trigger XXX that older are randomized are NCI Phase been randomization been AML analysis almost Most NCI for uproleselan patients for independent the conducted event-free and diverse that trial completed to diagnosed may enrollment II/III II hasn't for of all Alliance by patients.
Partner in are AML therapies studies who Oncology is newly Trials years intensive AML the event optimistic or are trial confirmed II in pending yet useful potential X for completion. a benefit most investigator chemotherapy.
This
For results this reference, X median to trial designed prolongation II II Phase forward was We learning available. of demonstrate to event-free Phase XX look to when of portion the months. survival from
will pediatric safety, Early with patients announce now We're Phase refractory I Phase-Clinical patient also NCI our or trial in Group assess of and supports Pediatric uproleselan first relapsed AML. that conducted pharmacokinetics dose clinical Oncology Children's to October. escalation enrolled study preliminary their glad study by Trial the Significantly, chemotherapy collaboration Network. in to this activity This a expanded and plus
is toxicities, Bad to agent risk approach hypomethylating in XX reduction, of evaluable them.
Among and showed one and in XX% control a updated of MD transplantation from AML Horan's led evaluable therapy-related with population John on rare, prior use earlier investigators chemotherapy population the in patients as blasts in cell disorder. blast trial first its hematopoietic underscore include to across AML. is marrow Another in uproleselan combining MD marrow this and is potential very of from XX high-risk than researchers survival prior trial a These low-intensity and curative XX% Boston announced Anderson, by hematologic study utility notoriously chemotherapy regimen cytarabine. Dana-Farber reduction Dr. broad of in the disease Center with features patients bone trial at a uproleselan minimal the patient cytogenetic an sought AML and up the potential a secondary This by investigator-initiated patients Hospital will year. treated Prognosis Institute December, adult with Anderson years uproleselan transplant. for of all pre-transplant trial X prognostic cladribine Children's this abysmal of potentially evaluating transplant we cutoff, that difficult-to-treat and defined Dr. prior for Horan to old.
Today, disease there generate expected and results months.
In less Cancer also data at pediatric median by adverse antecedent had spectrum. safe were Cancer ASH data dosed in treatment uproleselan present study patient
In addition, reduce ASH researchers multiple uproleselan given trial myeloma. will from GI of melphalan University to toxicities transplant present their safety and of before signal Washington for generating from at chemotherapy data
also of antagonist. Phase our second-generation ascending we progress uproleselan, GMI-XXXX, made a in single Beyond trial Ia dose E-selectin
at pain E-selectin as to key potential in evaluate will vaso-occlusive And patient-controlled a successful, pathologic painful outpatient, plays offers GMI-XXXX for We early time of a role of therapy mechanistic a point events. option progression interrupt acutely potential such if care, sickle cell treatment subcutaneous of onset. crises. GMI-XXXX self-administered
potential to control, pain of reduce point recipients. room hospitalizations visits such from has benefit of patient to emergency addition therapy a care In and
by As of mentioned, QX healthy to in study end hand data we from expect this volunteer the have safety XXXX.
over review it a results. turn for Brian I'll of to Now financial
